{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-004614","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.385912+00:00","generated_at":"2026-06-06T00:37:13.301108+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Windtree Therapeutics interim CFO John Tattory resigns; CEO takes over CFO role","bullets":["John A. Tattory resigned as Interim CFO effective Feb 15, 2024, by mutual agreement as part of cost-cutting measures, with no dispute.","CEO Craig E. Fraser will serve as principal financial officer on an interim basis while retaining President and CEO roles.","Tattory will continue consulting via LifeSci Associates at an agreed hourly rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-004614","json":"https://secwatch.observer/filing/0001437749-24-004614.json","markdown":"https://secwatch.observer/filing/0001437749-24-004614.md","text":"https://secwatch.observer/filing/0001437749-24-004614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774924004614/0001437749-24-004614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774924004614/wint20240215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:37:13.301108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"897f0d4bb8","claim":"Craig E. Fraser was appointed as Principal Financial Officer at WINDTREE THERAPEUTICS INC /DE/.","evidence_excerpt":"Craig E. Fraser, who currently serves as the Company’s President, Chief Executive Officer and Chairman of the Board of Directors, will assume the responsibilities of principal financial officer for purposes of the Securities Exchange Act of 1934, as amended, on an interim basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774924004614/0001437749-24-004614-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assumed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"abac95e6df","claim":"John A. Tattory resigned as Interim Chief Financial Officer at WINDTREE THERAPEUTICS INC /DE/.","evidence_excerpt":"On February 15, 2024, Windtree Therapeutics, Inc. (the “Company”) and John A. Tattory mutually agreed to Mr. Tattory’s resignation from his positions as the Interim Chief Financial Officer and principal financial officer of the Company, effective February 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774924004614/0001437749-24-004614-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}